Phase 1 Study of PRX019 in Healthy Adult Volunteers

Inclusion Criteria:

• Male and female participants who are healthy as determined by the investigator basedon review of medical history, physical examination, and clinical laboratory testsobtained during the screening period

• Participant is willing and able to adhere to the study visit schedule and otherprotocol requirements

Exclusion Criteria:

• Evidence of organ dysfunction or any clinically significant deviation from normal inphysical examination, vital signs, or clinical laboratory tests beyond what isconsistent with a healthy population in the region in which the study is conducted

• Participant was exposed to an investigational drug (new chemical entity) within 90days preceding the first dose administration, or within 7 times the eliminationhalf-life, if known (whichever is longer)

NOTE: Other protocol-defined inclusion/exclusion criteria apply